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The complement system  
 
The complement cascade is a unique sequence of 
molecular events occurring within the vascular system in 
which inactive plasma proteins synthesised by the liver 
are activated following tissue injury (Figure ) (McGavin 
and Zachary, 2007). The increase permeability of blood 
vessels during inflammation is stimulated, at least in part, 
by the complement system. The complement system is a 
complex system of 30 serum proteins. Many early 
components are serine proteases that are activated 
sequentially to form a cascade. The complement cascade 
is activated through any one, or more, of four pathways: 
the classical, the mannan-binding lectin (MBL), the 
alternative and the extrinsic protease pathways (Guo and 
Ward, 2005; Monk et al., 2007; Ricklin and Lambris, 
2007). For further information, refer (Manthey et al., 
2009). 
The classic pathway can be activated when IgG 
and/or IgM are cross linked with C1. C1 has three  
 
 
components: C1q, r and s. The first protein in the 
complement cascade, C1q, binds the Fc regions of IgG 
and/or IgM and brings C1r, which is proteolytic, into 
proximity to C1s, which is cleaved; through interactions 
with C2 and C4, and leads to the formation of classical 
pathway of C3 and C5 convertase. The MBL pathway is 
initiated by binding of the mannan-binding lectin, a 
serum protein, to mannose-containing carbohydrates on 
bacteria or viruses. Lastly, the alternative pathway of C3 
and C5 convertase can be initiated when a spontaneously 
activated complement component binds to the surface of 
a pathogen (microbial surface polysaccharides). A 
recently discovered fourth “extrinsic” activation pathway 
can also occur when endogenous proteases such as 
thrombin directly cleave the central complement 
components C3 and C5 (Guo and Ward, 2005; Hogan et 
al., 2004; Kirschfink, 1997; Monk et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1. Component and pathways of the complement cascade 
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The complement system bridges the innate and 
adaptive immune systems, which (respectively) based on 
non-specific recognition of foreign carbohydrates or 
specific recognition of foreign protein antigens. 
Complement proteins are chemotactic for inflammatory 
cells, such as monocytes and neutrophils, which, in turn, 
increase vascular permeability to enhance access into the 
infected and damaged area. Complement activation is 
also essential to the process of opsonisation where 
antigens entering the body are coated by complement. 
Opsonisation assists recognition by the antibody of a 
particular antigen prior to formation of the antigen-
antibody complex and phagocytosis (Rus et al., 2005). 
One of the complement of interest is the C5a that 
binds with similar high affinity to both C5a receptor 
(C5aR), CD88 and C5L2. C5aR belongs to the rhodopsin 
family of G-protein-coupled receptors (GPCR), and 
mediates most of the known activities of C5a (Gerard and 
Gerard, 1991; Vassilatis et al., 2003). C5L2 has a similar 
protein structure but is not G-protein coupled. Although 
C5a binds with high affinity to C5L2, few biological 
responses have been found for this interaction (Okinaga 
et al., 2003). C5L2 is present on neutrophils and 
immature dendritic cells (Ohno et al., 2000). C5aR 
expression was originally described on myeloids cells 
including neutrophils, leukocytes, eosinophils, basophils 
and monocytes (Chenoweth and Hugli, 1978; Gerard et 
al., 1989; Kurimoto et al., 1989; Monk et al., 2007; 
Werfel et al., 1992). More recently, C5aR has also been 
found on a variety of non-myeloids cells in many organs, 
especially in the lung and liver (Haviland et al., 1995; 
Schieferdecker et al., 2001). 
 
Possible role of C5a/C5aR, inflammation and the 
cardiovascular system 
  
The complement system is an innate immune 
mechanism activated in response to infection or injury. 
The complement activation product, C5a, is the most 
potent anaphylatoxin produced by the pathway, and by 
binding to its C5aR located on numerous cell types, it 
induces a wide range of inflammatory and immune 
effects (Guo and Ward, 2005), such as sepsis (Ward, 
2004), ischaemia-reperfusion injury (Arumugam et al., 
2002), arthritis (Woodruff et al., 2002) and asthma 
(Drouin et al., 2001). Besides that, C5a also acts as a 
potent chemoattractant to inflammatory cells (Guo and 
Ward, 2005). Activated neutrophils trigger the excessive 
production of reactive oxygen species (ROS) and the 
release of lyososomal enzymes that leads to necrosis of 
cells within local organs, and subsequent loss of organ 
function (Frangogiannis et al., 2002; Guo and Ward, 
2005). Thus, although complement activation may not be 
the initiating factor in disease, much of the subsequent 
damage to tissue may be complement-mediated. 
The complement system, particularly anaphylatoxin 
C5a and its receptor, C5aR, has a role in many diseases 
(Manthey et al., 2009), including cardiomyopathy 
(Afanasyeva and Rose, 2002). The complement receptor 
has been shown to play a significant role in myocardial 
ischaemia (Busche and Stahl, 2010; Monsinjon et al., 
2001; Yasojima et al., 1998; Zhang et al., 2007) and in 
other ischaemic diseases (specifically CD88, (Arumugam 
et al., 2004; Arumugam et al., 2007; Thundyil et al., 
2012). Furthermore, exposure to C5a will decrease the 
contractility of cardiomyocytes in vitro (Niederbichler et 
al., 2006), while inhibition of C5aR activity will reduce 
myocardial infarct size (Zhang et al., 2007) and 
ameliorate inflammation in myocardium (Hoesel et al., 
2007; Niederbichler et al., 2006; Vakeva et al., 1998; van 
der Pals et al., 2010). It is therefore possible that 
complement, particularly, C5aR, may play a role in the 
pathogenesis and/or progression of HCM. The question 
that must be asked is: If inflammation is evident in the 
myocardium of cats with HCM (Khor et al., 2015), will 
C5aR (specifically CD88) play a major role eliciting the 
associated inflammatory response? In addition, do any 
changes in CD88 receptor density contribute to affect the 
activity of β-adrenoreceptors, particularly since an 
interaction between adrenoreceptors and the complement 
system has been identified.  
 
Inflammation and Hypertrophic Cardiomyopathy 
 
Hypertrophic cardiomyopathy (HCM) is a primary 
myocardial disease characterised by concentric left 
ventricular hypertrophy associated with diastolic 
dysfunction and arrhythmias. The disease progression of 
HCM is variable with congestive heart failure being an 
important clinical outcome. Treatment is challenging and 
usually focuses on attempts to delay onset or control 
signs of congestive heart failure and reduce the risk of 
systemic thromboembolism and sudden death.  
HCM has a wide range of histopathological 
abnormalities but myocardial fibre disarray is a 
distinctive hallmark of HCM. The myocytes are arranged 
in chaotic, disorganised patterns at oblique and/or 
perpendicular angle which appeared in a bizarre 
disorganised cellular architecture (Figure 2) (Baty et al., 
2001; Fox, 2003; Khor et al., 2015; Kittleson and Kienle, 
1998; Liu et al., 1993; Nakagawa et al., 2002; Tilley et 
al., 1977).  
 
 
Figure 2. A cat with pre-clinical hypertrophic 
cardiomyopathy, the latter demonstrating an area of 
myocardial fibre disarray with disordered 
arrangement of cardiac muscle cells at oblique angles 
to each other (Khor et al., 2015) 
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Other histopathological findings are hypertrophied 
myocytes, increased collagen deposition (Khor et al., 
2015) resulting interstitial fibrosis and abnormalities of 
the intramyocardial small vessels (Cesta et al., 2005; 
Fox, 2003; Liu et al., 1993; Nakagawa et al., 2002; 
Varnava et al., 2000). It is likely that these abnormal 
structural changes disrupt the transmission of 
electrophysiology impulses predisposing the diseased 
heart to diastolic dysfunction and ventricular 
tachyarrhythmia (Fox, 2003; Kittleson and Kienle, 1998; 
Liu et al., 1981; Liu et al., 1993; Tilley et al., 1977).  
The frequency of each abnormality observed varied 
between HCM cats (Liu et al., 1993). Liu et al. (1981) 
found 25% of the HCM cats (n=51) observed with 
asymmetric left ventricular hypertrophy had myocardial 
fibre disarray in the IVS. In other HCM hearts, only 
myocyte hypertrophy was evident or some had moderate-
to-severe interstitial. Replacement fibrosis was present in 
about 20 - 40% of HCM cases (Liu et al., 1993). The 
histopathological findings differ between HCM hearts 
probably due to cardiac remodelling which occurs at 
different stages of the disease, maybe depending on the 
extent of the damage. The pre-clinical HCM cats have 
similar histopathological findings at the early stage 
despite detectable functional changes. Interestingly, 
recent study by Khor et. al. (2015) shown that the left 
myocardium of cats with pre-clinical HCM has 
multifocal areas of inflammatory cell infiltration, 
predominantly lymphocytes, were observed frequently. 
Tissue from cats with pre-clinical HCM also had a higher 
number of neutrophils and a greater collagen content than 
the myocardium of normal cats(Khor et al., 2015). 
It was then hypothesised that early (pre-clinical) 
HCM was characterised by, and possibly initiated by, 
inflammatory events (Khor et al., 2015; Khor et al., 
2013), in addition to any increase in left ventricle wall 
thickness in diastole and evidence of diastolic 
dysfunction. Infiltration of inflammatory cells into 
myocardial tissue(Khor et al., 2013) appeared to occur 
prior to the onset of structural and functional changes 
may therefore contribute to disease pathogenesis and/or 
efficacy of pharmacological agents used to treat HCM. It 
would be interesting to determine if this observation is 
the same in cats with more severe HCM. Further studies 
that include immunohistochemical myocardial staining 
and evaluate circulating inflammatory cytokines are 
indicated to better characterise the role of inflammation 
in the pathogenesis and early development of fibrosis in 
feline HCM.  
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